To clarify the mechanism by which Morgana is downregulated in CML patients remains a crucial point to understand the onset and progression of this pathology and, consequently, to choose the best therapy to avoid resistance and design therapeutic interventions for MDS/MPN with neutrophilia patients, for which overall survival remains very poor10,31–33. This evidence concerns the gene CHORDC1 and myelodysplastic syndrome.